The Virginia Cancer Institute (VCI) website is intended to provide general information about the Institute, its care and research programs, and about cancer and related diseases. This site also provides links to health information that may be written by Virginia Cancer Institute staff or by outside providers, and access (links) to some external websites for your convenience. VCI is not responsible for the availability, accuracy, or content of these external sites, nor does it endorse them.
NO MEDICAL ADVICE GIVEN
This site is not an attempt to practice medicine or provide specific medical advice, nor does the use of the site establish a doctor-patient relationship. For medical treatment or answers to personal questions, we strongly encourage you to consult with a qualified health care provider. For advice about your own care, please ask your doctor.
RESTRICTIONS ON USE
You assume full responsibility for using the information on this site, and you understand and agree that VCI is not responsible or liable for any claim, loss, or damage resulting from its use. While we try to keep the information on the site as accurate as possible, we disclaim any warranty concerning its accuracy, timeliness, and completeness, and any other warranty, express or implied, including warranties of merchantability or fitness for a particular purpose. VCI also does not warrant that access to the site will be error- or virus-free.
The VCI website does not host or receive funding from advertising.
Material on the VCI website is protected by copyright law. Unless otherwise stated, users may print or download information from this site for personal, non-commercial use only. Permission to reprint or otherwise reproduce any document in whole or in part is prohibited, unless prior written consent is obtained from the copyright owner.
INFORMATION FOR REPORTING CLAIMS OF COPYRIGHT INFRINGEMENT
In accordance with the Digital Millennium Copyright Act, 17 U.S.C. § 512 (the “DCMA”) Virginia Cancer Institute, Inc. (“VCI”) is registered as a Service Provider with the United States Copyright Office. Notifications of copyright infringement claims occurring on VCI’s network should be reported to VCI.
Any such notice must be in writing, and must include the following information as required by the DMCA:
- A physical or electronic signature of the copyright owner or the person authorized to act on its behalf;
- A description of the copyrighted work claimed to have been infringed;
- A description of the infringing material and information reasonably sufficient to permit Virginia Cancer Institute to locate the material;
- Your contact information, including your address, telephone number, and email;
- A statement by you that you have a good faith belief that use of the material in the manner complained of is not authorized by the copyright owner, its agent or the law; and
- A statement that the information in the notification is accurate, and, under the pains and penalties of perjury, that you are authorized to act on behalf of the copyright owner.
Content of this website is licensed from CancerConsultants.com, the premier cancer treatment information provider. CancerConsultants provides patients and their families with an independent and comprehensive source of current cancer treatment information. We encourage you to visit this website often as information is continuously updated.
CancerConsultants utilizes leading cancer practitioners and researchers with extensive experience in oncology practice, research and drug development to provide and review the content presented on the web site. Contributing editors are asked to provide information that helps cancer patients to be prepared and informed when they discuss their cancer treatment options with their physicians.
Editorial Policy: The editors of the CancerConsultants develop and write all of the content information presented in the Patient Resource Center and retain sole and complete editorial control of the content. The posting of clinical trials on the Patient Resource Center is performed in exchange for a listing fee. All trials have been approved by the designated institutional review board for the institution conducting the trial prior to posting.
C. Dean Buckner, M.D., Scientific Editor
Dr. Buckner is a graduate of the University of Michigan Medical School and received his residency and post-graduate hematology and oncology training at the University of Washington and the National Cancer Institute. He helped pioneer autologous and allogeneic bone marrow and blood stem cell transplantation as a treatment for cancer with the team headed by E. Donnall Thomas, who received the 1990 Nobel Prize in Medicine for his work on transplantation biology. Dr. Buckner was a founding member of the Fred Hutchinson Cancer Research Center and Director of the Autologous Marrow Transplant Program. He has authored over 400 publications in the field of hematology and oncology, including many in the New England Journal of Medicine. In 1987, Dr. Buckner was awarded the Joseph Steiner award for achievements in bone marrow transplantation research. He is a founding board member of the Jose Carreras Foundation Against Leukemia and serves on several editorial boards. As a member of the National Cancer Institute grant review process, Dr. Buckner remains active in evaluating the quality of cancer research programs eligible to receive federal research funding. He is an advocate of promoting access to cancer care and clinical trials in the community setting.
Charles H. Weaver M.D., Managing Editor
Charles H. Weaver, M.D. is the founder of CancerConsultants.com. Dr. Weaver is a medical oncologist who trained at the University of Pennsylvania, National Institutes of Health, and Fred Hutchinson Cancer Research Center. He spent five years as Chief Medical Officer at Response Oncology Inc. In his role at Response Oncology, he developed and implemented the strategy for interfacing with biopharmaceutical companies, established the clinical research organization, created the site management organization and developed the managed care strategy. Dr. Weaver brings to CancerConsultants.com a wealth of knowledge and experience in the clinical and business practice of oncology. He has extensive contacts throughout the oncology pharmaceutical industry. He has a well-established record of collaborating in clinical research with the biopharmaceutical industry and has authored more than 100 publications.
Kevin A. Schulman M.D., Co-Editor
Kevin A. Schulman, M.D., is Professor of Medicine at the Duke University School of Medicine and Director of the Center for Clinical and Genetic Economics at Duke Clinical Research Institute. Dr. Schulman is an expert in technology assessment related to new pharmaceutical products and new clinical therapies, and is the principal outcomes investigator for many major multinational clinical trials, including several related to supportive care treatments in oncology. Dr. Schulman is the author of over 100 peer-reviewed articles, book chapters, editorials and reviews, and over 100 abstracts. Dr. Schulman is also a member of the editorial board of seven major medical journals.
The Patient Resource Center web site and service is free to patients and their families. To ensure easy reading, free of distractions, advertising is not sold on the Patient Resource Center.
Manufacturers of biopharmaceutical products, however, may sponsor content development and have their product hyperlinked within the Patient Resource Center content sections so that readers may directly access additional product information from the manufacturers when desired.
|Acute Leukemias||C. D. Buckner, MD||OncoEd, Inc.|
|Breast Cancer||Lee Schwartzberg, MD||The West Clinic|
|Chronic Leukemias||C. D. Buckner, MD||OncoEd, Inc.|
|GI Malignancies||Charles R. Thomas, Jr., MD||Univ of Texas, San Antonia|
|Gene Therapy||John Nemunaitis, MD||Baylor|
|Gynecologic Oncology||Gazi Abdulhay, MD||Lehigh Valley Women’s Cancer Center|
|Head and Neck Cancer||John W. Rieke, MD||Univ of WA, Seattle|
|Hodgkin’s Disease||James O. Armitage, MD||Univ of Nebraska|
|Lung Cancer||Anthony Greco, MD||Sarah Cannon Cancer Center|
|Malignant Melanoma||Jance Cormier, MD||MD Anderson|
|Mesothelioma||Nicholas J. Vogelzang, MD||Nevada Cancer Institute|
|Multiple Myeloma||William Bensinger, MD||Fred Hutchinson Cancer Research Center|
|Non-Hodgkin’s Lymphoma||James O. Armitage, MD||Univ of Nebraska|
|Pathology||Thomas J. Moss, MD||MT Associates|
|Pathology||Marc D. Siegel, MD||MT Associates|
|Pediatric Oncology||Frank Smith, III, MD||Cincinnati Children’s Hospital Medical Center|
|Prostate Cancer||David E. Crawford, MD||Univ of Colorado, Professor of Surgery and Radiation Oncology|
|Radiation Oncology||Charles R. Thomas, Jr., MD||Univ of Texas, San Antonio|
|Renal Cell Cancer||John S. Lam, MD||UCLA|